Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – ...

The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...

The findings mean that for those using preexposure prophylaxis with gender-affirming hormone therapy or long-acting hormonal ...

Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) are dedicated to bringing novel treatments to ...

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 ...

Brekiya® is now available for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster presentation highlighting extended follow up analyses examining ...

† Department of Chemistry, Washington State University, Pullman, Washington 99164, United States ‡ Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, ...

Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company and its corporate parent, Shin Nippon Biomedical ...

AVEO Oncology, an LG Chem company (AVEO), and HiberCell, Inc. (HiberCell) announced today that the companies have entered ...

Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025 Multiple real-world analyses and an analysis ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported ...